Article
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Breast cancer research : BCR - 27 Jul 2017
Toomey Sinead, Eustace Alexander J, Fay Joanna, Sheehan Katherine M, Carr Aoife, Milewska Malgorzata, Madden Stephen F, Teiserskiene Ausra, Kay Elaine W, O'Donovan Norma, Gallagher William, Grogan Liam, Breathnach Oscar, Walshe Janice, Kelly Catherine, Moulton Brian, Kennedy M John, Gullo Guiseppe, Hill Arnold D, Power Colm, Duke Deirdre, Hambly Niamh, Crown John, Hennessy Bryan T
Abstract excerpt
BACKGROUND: The Cancer Genome Atlas analysis revealed that somatic EGFR, receptor tyrosine-protein kinase erbB-2 (ERBB2), Erb-B2 receptor tyrosine kinase 3 (ERBB3) and Erb-B2 receptor tyrosine kinase 4 (ERBB4) gene mutations (ERBB family mutations) occur alone or co-occur with somatic mutations in the gene encoding the phosphatidylinositol 3-kinase (PI3K) catalytic subunit (PIK3CA) in 19% of human epidermal...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.